Abstract | OBJECTIVE: To report 2-year patient-reported outcomes (PROs) from the head-to-head Abatacept versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate (MTX) (AMPLE) trial. METHODS: AMPLE was a phase IIIb, randomized, investigator-blinded trial. Biologic-naive patients with rheumatoid arthritis (RA) and an inadequate response to MTX were randomized to subcutaneous (SC) abatacept (125 mg/week) or adalimumab (40 mg every 2 weeks) with background MTX. PROs ( pain, fatigue, ability to perform work, and ability to perform daily activities) were compared up to year 2 for patients in each treatment group, as well as those who achieved low disease activity at both years 1 and 2 (responders) and those who did not (nonresponders). RESULTS: A total of 646 patients were randomized and treated with SC abatacept (n = 318) or adalimumab (n = 328). Baseline characteristics were balanced between the 2 treatment arms. Comparable improvements in PROs were observed in the abatacept and adalimumab groups over 2 years, with both groups achieving clinically meaningful improvements in PROs from baseline. At year 2, fatigue improved by 23.4 mm and 21.5 mm on a 100-mm visual analog scale with abatacept and adalimumab, respectively. Clinical responders achieved greater improvements in PROs than nonresponders. CONCLUSION: In biologic-naive patients with active RA, despite prior MTX, treatment with SC abatacept or adalimumab with background MTX resulted in comparable improvements in PROs, which were highly correlated with physician-reported clinical response end points.
|
Authors | Roy Fleischmann, Michael E Weinblatt, Michael Schiff, Dinesh Khanna, Michael A Maldonado, Anagha Nadkarni, Daniel E Furst |
Journal | Arthritis care & research
(Arthritis Care Res (Hoboken))
Vol. 68
Issue 7
Pg. 907-13
(07 2016)
ISSN: 2151-4658 [Electronic] United States |
PMID | 26473625
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2016 The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology. |
Chemical References |
- Antirheumatic Agents
- Abatacept
- Adalimumab
|
Topics |
- Abatacept
(therapeutic use)
- Adalimumab
(therapeutic use)
- Adult
- Aged
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Rheumatoid
(drug therapy)
- Female
- Humans
- Injections, Subcutaneous
- Male
- Middle Aged
- Patient Reported Outcome Measures
- Treatment Outcome
|